NASDAQ, CYCC - Cyclacel Pharmaceuti

We are a clinical-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. We describe drugs, compounds or molecules as mechanism-targeted if they are designed to affect identified biological processes through known mechanisms and novel if they have been recently discovered using advanced technologies. Our core area of expertise is in cell cycle biology, or the processes by which cells divide and multiply. We focus primarily on the discovery and development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors, and enhancing quality of life and improving survival rates of cancer patients. We have been focused on the cell cycle since our inception. We were founded in 1996 by Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology who discovered the p53 protein, which operates as one of the body's own anticancer "drugs" by inhibiting cell cycle targets.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	0.0819
PEG Ratio:	N/A
EPS:	43.2
DivYield:	N/A
PtB:	0.9989
PtS:	N/A
EBITDA:	N/A
Shares:	23.76M
Market Cap:	208.61M
52wk range:	0.17 - 19.87

216.73.216.229
United States